Today: 29 June 2026
NTPC share price rises as a ₹380 buy call lands, but MarketsMojo sticks to ‘Sell’
20 January 2026
2 mins read

NTPC share price rises as a ₹380 buy call lands, but MarketsMojo sticks to ‘Sell’

Mumbai, January 20, 2026, 11:39 IST

  • NTPC hovered between Rs 345 and 347 in late morning trade on Tuesday, following a stronger start to the session
  • A Mirae Asset Sharekhan strategist highlighted a buy range between Rs 342 and Rs 346, setting a target of Rs 380
  • MarketsMojo stuck with a ‘Sell’ rating, highlighting limited returns and elevated leverage ratios

Shares of NTPC Ltd nudged up in early Tuesday trading, hovering around Rs 345.05 by 11:24 a.m. IST, marking a roughly 0.5% gain for the day. The stock had earlier touched Rs 347.30, according to a live update from The Economic Times. By that time, roughly 3.39 million shares changed hands, and the price-to-earnings ratio stood at 14.15.

NTPC’s shifts carry weight, as it ranks among India’s largest listed utilities and is a staple in many portfolios for its defensive, dividend-driven appeal. When investors pivot to more stable large caps, stocks like this often attract quick follow-up buying.

NTPC faces a tug-of-war: short-term chart traders eyeing a breakout versus screens flagging ongoing balance-sheet stress. Each group has the power to drive the stock—and the potential to exit fast if key levels falter.

Somil Mehta, head of alternate research and capital market strategy at Mirae Asset Sharekhan, advised buying NTPC between Rs 342 and Rs 346, setting a stop loss at Rs 328 and aiming for Rs 380, the Times of India reported. He called it a “descending trendline breakout” and noted “momentum indicators are positive.” A stop loss here serves as a preset limit to cut losses, while moving averages help smooth out daily price fluctuations. The Times of India

MarketsMojo, which ranks stocks using its “Mojo Score,” kept NTPC at ‘Sell,’ with the last update on Nov. 10, 2025, when the score dropped from 55 to 42. The current report uses data through Jan. 20, 2026. It highlighted an average return on capital employed (ROCE) of 8.24% and a debt-to-EBITDA ratio of 4.81 times, while the technical outlook came in as mildly bearish. (ROCE measures profitability against capital, and debt-to-EBITDA compares debt levels to operating earnings.) Markets Mojo

The scale of NTPC works both for and against it. While its regulated status and size help stabilize cash flow, hefty expansion projects and older thermal plants may keep leverage high and returns limited—particularly if input costs rise or tariff regulations change.

In the power sector, investors often pit NTPC against peers like Tata Power and Torrent Power, each with their own blend of renewable and conventional assets. The debate tends to focus less on short-term price moves and more on execution and how much room they have on the balance sheet.

The chart trade can quickly reverse. Should the broader market shift or changes in policy and fuel-cost assumptions hit the sector, the stock may fall below support levels, pushing short-term buyers to sell off their positions.

NTPC jumped 3.43% earlier this month, hitting Rs 349.5 in one session, and then pushed higher for a third day running, Business Standard reported. Trading volume stood at 102.16 lakh shares, above the one-month daily average of 92.27 lakh.

NTPC currently balances between a trader’s bullish target and a screener’s caution flags on profitability and leverage. Investors will be focused on upcoming earnings, project updates, and any policy changes to gauge if returns can rise without taking on more debt.

++

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Novo Nordisk (NVO) holds lead in obesity drugs as Viking Therapeutics (VKTX) trials new rival
    June 29, 2026, 1:12 PM EDT. Novo Nordisk (NVO) is still the leader in obesity drugs, claiming 54.6% of the market for 2025 with its GLP-1 drugs Ozempic, Rybelsus, and Wegovy. The FDA just cleared its 25 mg oral semaglutide-Wegovy in pill form-for obesity and heart disease, with more than three million scripts written since launch. Viking Therapeutics (VKTX), still in the clinic, is betting on VK2735, a dual GIP and GLP-1 receptor agonist that's showing early promise but carries more R&D risk. As demand for new weight-loss drugs grows, investors are weighing the certainty of NVO's established sales against VKTX's possible future gains.
SEBI listing-rule revamp sparks MSEI unlisted share rally and a hiring rush at NSE, BSE
Previous Story

SEBI listing-rule revamp sparks MSEI unlisted share rally and a hiring rush at NSE, BSE

OpenAI CFO Sarah Friar lifts lid on $20B revenue run rate as 2026 shifts to “practical adoption”
Next Story

OpenAI CFO Sarah Friar lifts lid on $20B revenue run rate as 2026 shifts to “practical adoption”

Go toTop